EPO administration ameliorated glucose metabolism in haemodialysis patients8, 9 and reduced blood glucose levels in healthy mice, as well as in murine diabetes and obesity models5, 10, 11, 12. Here, EPO is linked to obesity due to melanocortin 4 receptor deficiency.